2186:HKEXLuye Pharma Group Ltd. Analysis

Luye Pharma is trading at HK$1.88, just above its 30‑day low of HK$1.74 and well below the DCF‑derived fair value of HK$4.28, implying an upside of roughly 88%. Technical indicators are bearish: the 20‑day SMA (HK$2.18) sits under the price, RSI is at 29 indicating oversold conditions, and the MACD histogram is negative, while the 30‑day volatility spikes above 57% and the max drawdown exceeds 60%, underscoring short‑term risk.
Fundamentally, the stock appears deeply undervalued – its trailing P/E of 13.4 is well under the industry average of 24.9, and the P/B of 0.40 is far below 1.0. Revenue growth of 4.7% and a solid gross margin of 66% provide a modest growth backdrop, but free cash flow is negative and debt‑to‑equity is high at 56, highlighting liquidity concerns. The forward P/E of 7 and a forward EPS growth trajectory suggest the earnings base may improve, offering a compelling long‑term catalyst despite current cash‑flow constraints.